Nachrichten zur Hims & Hers Health Inc. Aktie

Why Did Hims & Hers Stock Collapse 50% in Early 2026?

Hims & Hers stock has collapsed over 50% in 2026 alone, yet a mid-case valuation model still prices it at…

What To Expect From Hims & Hers Health’s (HIMS) Q4 Earnings

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.…

What To Expect From Hims & Hers Health’s (HIMS) Q4 Earnings

Telehealth company Hims & Hers Health NYSE:HIMS will be announcing earnings results this Monday after market close. Here’s what to…

Hims & Hers Health (HIMS) Surges on Eucalyptus Acquisition

Key Takeaways: Hims & Hers Health (HIMS) is expanding its digital health portfolio with the acquisition of…

Key deals this week: Visa, Hims & Hers Health, Salesforce and more

Track this week’s biggest M&A deals: Visa, Salesforce, Hims & Hers, Danaher/Masimo, BlueScope, Kennedy-Wilson and Qube.…

Hims & Hers Health To Acquire Eucalyptus In Up To $1.15 Billion Cash-And-Stock Deal

Hims & Hers Health announced it has entered into a definitive agreement to acquire Eucalyptus, an international digital health company,…

Hims & Hers in Free Fall: Why Analysts See Nearly 150% Upside

HIMS is down 48% in the past month following a Novo Nordisk lawsuit. But, analysts expect record revenue when the…

Hims & Hers Goes Global While GLP-1 Drama Plays Out at Home

Hims & Hers is planting its flag in new overseas markets; on U.S. soil, its navigating a GLP-1s fight against…

Hims & Hers $1.2 Billion Global Leap: Can Eucalyptus Cure its GLP-1 Ills?

Hims & Hers Health (NYSE:HIMS) just made a bold move to take its personalized wellness platform global. The company announced…

Hims & Hers to acquire Eucalyptus for US$1.15bn

Hims & Hers has agreed to buy Eucalyptus in a deal worth up to US$1.15bn, expanding its international digital health…

Hims & Hers: Strategic Eucalyptus Acquisition Accelerates Global Telehealth and Obesity-Care Growth, Supporting Buy Rating

Hims & Hers Health, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst David Larsen from…

Hims & Hers HUGE Acquisition News!

Hims & Hers is acquiring Eucalyptus and spreading its wings internationally.…

Hims & Hers plans to acquire Eucalyptus for $1.15B

The acquisition of the international telehealth company will allow Hims & Hers to expand its presence in Australia, Japan, Germany,…

Hims & Hers to Acquire Eucalyptus in $1B+ Deal

Foreign relations.…

Hims & Hers eyes international growth with $1.15B Eucalyptus acquisition

Consumer health and wellness platform Hims & Hers will ramp up its international presence with the acquisition of Australian digital…

Hims & Hers Acquires Australian Digital Health Eucalyptus for Up to $1.15B

ims & Hers Health, Inc. has entered into an agreement to acquire Eucalyptus, an international digital health company for $1.15…

Hims & Hers Health Stock Resumes Climb on Acquisition News

Hims & Hers Health (HIMS) shares are higher today after the company revealed its $1.15 billion acquisition for Australian-based Eucalyptus…

Hims & Hers buys Australian digital health firm for $1.15bn

Hims & Hers, facing a threat to its compounded medicines business, has ramped up its push for international expansion by…

What Is HIMS Worth Without GLP-1? Earnings Preview

At $16, Hims & Hers Health stock is cheap on sales metrics, but upside is capped pending regulatory clarity and…

Why Is Hims & Hers Health Stock Trading Higher Today? - Hims & Hers Health (NYSE:HIMS)

Hims & Hers stock rises premarket after announcing a $1.15 billion deal to acquire Eucalyptus and expand global reach.…

Hims & Hers is spending more than $1 billion in a push to expand globally

Hims & Hers’ stock surges as a $1.2 billion deal to buy an Australia-based telehealth company affirms the health-and-wellness company’s…

Hims & Hers to acquire Australian digital health firm Eucalyptus, expanding international footprint

Hims & Hers (NYSE:HIMS) announced on Thursday that it has entered a definitive agreement to acquire Australian digital health company Eucalyptus…

Hims & Hers Stock Jumps on $1.15 Billion Deal to Acquire Australian Telehealth Provider

Hims & Hers Health will buy Eucalyptus, an Australian digital health company, in a deal valued at $1.15 billion.…

Hims & Hers to Acquire Eucalyptus in $1.15 Billion Deal

Hims & Hers Health has agreed to acquire digital health company Eucalyptus in a deal valued at $1.15 billion in…

Hims & Hers stock rises after agreement to acquire Eucalyptus By Investing.com

Hims & Hers stock rises after agreement to acquire Eucalyptus…

Hims & Hers to buy Australian digital health firm Eucalyptus for over $1B

Hims & Hers (HIMS) stock jumps as the company agrees to buy Eucalyptus, an Australian digital health provider, in a…

Hims to buy Eucalyptus as it looks to expand globally

Hims & Hers is buying the Australian telehealth firm Eucalyptus as it looks to make inroads in more countries globally.…

Hims & Hers Health to acquire Australias Eucalyptus for up to $1.15 billion

The deal would ?give Hims & Hers a foothold in Australia and Japan while deepening its presence in ?the United…

Hims & Hers Health to acquire Australia’s Eucalyptus for up to $1.15 billion By Reuters

Hims & Hers Health to acquire Australia’s Eucalyptus for up to $1.15 billion…

Hims & Hers to Acquire Eucalyptus in Deal Valued Up to $1.15 Billion

Hims & Hers entered into a Securities Sale Deed to acquire all of the equity of Eucalyptus for up to…

Hims & Hers GLP-1 pill gambit backfires, accelerating crackdown on drug compounders

Online telehealth company Hims & Hers Health , seeking growth drivers as its original sexual-health franchises matured, may have overstepped…

Analysis-Hims & Hers GLP-1 pill gambit backfires, accelerating crackdown on drug compounders

NEW YORK, Feb 19 (Reuters) - Online telehealth company Hims & Hers Health, seeking growth drivers as its original sexual-health…

Hims & Hers’ $1.15B global telehealth push with Eucalyptus buy

Eucalyptus brings $450M ARR, 775,000 customers and brands like Juniper and Pilot, as Hims & Hers plans expansion across Australia,…

Hims & Hers under fire over copycat weight loss drugs

Hims & Hers is facing battles on multiple fronts as it seeks to maintain its lucrative business in copycat weight…

Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform

Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced it has entered into a…

How We’re Becoming the Leading Global Consumer Health Platform

Last year, I said that the value of what we’re building for customers at Hims & Hers isn’t restricted to…

Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform

Eucalyptus is a consumer healthcare leader in Australia, the UK and Germany, with expanding new operations in Japan and Canada.…

Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts

In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $15.84, marking a -2.64% move from the…

Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts

In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $15.84, marking a -2.64% move from the…

Hims And Hers Weighs Legal Risks Against Growth In Longevity Pivot

Hims & Hers Health (NYSE:HIMS) launched a compounded semaglutide weight loss pill, then quickly discontinued it after a patent infringement…

Hims And Hers Faces GLP-1 Setback While Expanding Into Longevity Care

Hims & Hers Health (NYSE:HIMS) has halted its newly launched compounded GLP-1 weight loss pill only days after introducing it.The…

Hims & Hers Health: 5 Key Questions Ahead Of Critical Q4 Earnings

Hims & Hers Health, Inc. faces volatile earnings as compounded GLP-1 setbacks pressure shares. Click for this HIMS stock earnings…

Deutsche Bank Cite Near-Term Growth Concerns For Hims & Hers Health, Inc. (HIMS) Following GLP-1 Launch Reversal

Hims & Hers Health, Inc. (NYSE:HIMS) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts. Hims &…

Hims Has Outmaneuvered Novo For Years. Is Its Time Up?

Novo Nordisk and the FDA are both mounting pressure on Hims & Hers Health and other GLP-1 compounders.…

Hims & Hers Health (HIMS) Is Down 5.5% After Novo Nordisk GLP-1 Lawsuit and FDA Scrutiny

In early February 2026, Novo Nordisk filed a patent infringement lawsuit against Hims & Hers over its compounded semaglutide weight-loss…

Novo Nordisk Patent Fight With Hims And Hers Puts Valuation In Focus

Novo Nordisk has filed a lawsuit against Hims & Hers Health accusing it of infringing patents related to its obesity…

Wall Street Sees 84% Upside in Hims & Hers (HIMS) Despite This Months 48% Selloff

Hims & Hers Health (NYSE:HIMS) has crashed 47.96% over the past month, falling from $31.32 on January 14 to $16.30…

Hims & Hers Health Stock (HIMS) Opinions on Earnings Beat

Earnings surge ignites debate: Hims & Hers Health reported robust quarterly results, fueling widespread chatter on social media. Investors praised…

Hims & Hers is a brave bet on solving the disruptor’s dilemma

Plan to make longevity affordable means muscling in on territory occupied by drugs giants and pharmacies…

Hims & Hers Health (HIMS) Is Down 29.2% After Semaglutide Lawsuit And DOJ Referral - Has The Bull Case Changed?

Earlier in February 2026, Novo Nordisk sued Hims & Hers Health over its compounded semaglutide products, following the rapid launch…